Induced selective radioiodine uptake by the thyroid gland is the basis for thyroid cancer therapy. Various agents have been tested to increase radioiodine uptake in patients with deficient sodium iodide transporter (NIS). Salivary gland dysfunction is a common and serious complication of radioiodine therapy.

Liu and colleagues demonstrate increased thyroidal, but not salivary gland, uptake of radioiodine in mice treated with 17-allyamino-17-demothoxygeldanamycin (17-AAG). Liu et al. (2010) Endocrine-Related Cancer accepted preprint.

Read the full article at DOI: 10.1677/ERC-10-0185.